Prostate Cancer Clinical Trials in Seattle

Showing 141-160 of 183 trials

Docetaxel in Treating Patients With Relapsed Prostate Cancer

NCT00482274

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well docetaxel works in treating patients with relapsed prostate cancer.

Prostate Cancer

OHSU Knight Cancer Institute3 participantsStarted May 2007

Portland, Oregon, United States • Seattle, Washington, United States

COMPLETEDPhase 2< 1 mile

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

NCT00769795

The purpose of this study is to determine whether combination treatment of prostate cancer with IMC-A12 (an antibody which blocks insulin-like growth factor receptor activity) with hormonal therapy (testosterone lowering) before prostatectomy, will be more effective than prior results with hormonal therapy alone.

Prostate Cancer

University of Washington29 participantsStarted Oct 2008

Seattle, Washington, United States • Seattle, Washington, United States • Seattle, Washington, United States

COMPLETEDNA< 1 mile

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

NCT02080689

The influence of Decipher test on urologist and patient treatment plan choices immediately post RP and at the time of PSA rise or BCR

Prostate Cancer

GenomeDx Biosciences Corp286 participantsStarted May 2014

Anchorage, Alaska, United States • Los Angeles, California, United States • Aurora, Colorado, United States +16 more locations

Docetaxel in Treating Patients With Relapsed Prostate Cancer

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Prostate Cancer Trials in Other Cities

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Effects of ASA on Prostate Tissue

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

A Trial of Degarelix in Patients With Prostate Cancer

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy

Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Other Conditions in Seattle